Bleeding Issues in Women Under Oral Anticoagulation

Area of Science:

• Pharmacology
• Gynecology
• Hematology

Background:

• Direct oral anticoagulants (DOACs) are increasingly used for venous thromboembolism (VTE).
• Previous studies suggest a potential link between DOACs and heavy menstrual bleeding (HMB) in premenopausal women, but findings are limited by study design and definitions.
• Information on contraceptive use influencing HMB during anticoagulation is often lacking.

Purpose of the Study:

• To address the need for prospective studies investigating HMB in women on oral anticoagulation.
• To compare the incidence of HMB in women of reproductive age treated with different DOACs for VTE.
• To evaluate HMB independently of oral contraceptives or intrauterine devices.

Main Methods:

• An ongoing multicenter German registry is collecting data on consecutive women aged 18-50 years.
• The registry focuses on women treated with DOACs for venous thromboembolism.
• The study aims to compare HMB incidence across different DOACs.

Main Results:

• Data collection is ongoing; specific results are not yet available.
• The study is designed to provide robust data on HMB incidence and severity.
• Findings will help clarify the association between DOACs and HMB.

Conclusions:

• Prospective, standardized studies are essential to accurately assess HMB risk with DOACs.
• Understanding HMB in women on anticoagulation requires consideration of contraceptive methods.
• The German registry aims to provide crucial evidence for managing HMB in this population.